Chemed (CHE) Competitors

Chemed (NYSE:CHE) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Does the media favor CHE or MEDP?

In the previous week, Medpace had 4 more articles in the media than Chemed. MarketBeat recorded 12 mentions for Medpace and 8 mentions for Chemed. Medpace's average media sentiment score of 1.09 beat Chemed's score of 0.88 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemed	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	7 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in CHE or MEDP?

95.9% of Chemed shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 3.3% of Chemed shares are owned by insiders. Comparatively, 20.3% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is CHE or MEDP more profitable?

Medpace has a net margin of 18.74% compared to Chemed's net margin of 11.56%. Medpace's return on equity of 67.66% beat Chemed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemed	11.56%	25.83%	17.77%
Medpace	18.74%	67.66%	21.86%

Which has more risk & volatility, CHE or MEDP?

Chemed has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Which has better valuation and earnings, CHE or MEDP?

Medpace has lower revenue, but higher earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemed	$2.43B	2.62	$302M	$19.45	22.48
Medpace	$2.23B	6.66	$404.39M	$13.45	39.31

Do analysts recommend CHE or MEDP?

Chemed currently has a consensus price target of $578.50, suggesting a potential upside of 32.29%. Medpace has a consensus price target of $422.27, suggesting a potential downside of 20.13%. Given Chemed's stronger consensus rating and higher possible upside, equities analysts clearly believe Chemed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemed	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Medpace	3 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Medpace beats Chemed on 10 of the 16 factors compared between the two stocks.